Results 171 to 180 of about 790,096 (261)

Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data

Eye, 2019
Ashish Sharma, M. Faridi, Nilesh Kumar, N. Parachuri, Rohini Sharma, B. Kuppermann, F. Bandello, A. Loewenstein, C. Regillo   +8 more
semanticscholar   +1 more source

Why Product Drift Is Not an Issue for Biosimilars/Biologics: Start the Same, Stay the Same. [PDF]

BioDrugs
Park JP, Oh H, Woollett GR.
europepmc   +1 more source

Peep into anti-vascular endothelial growth factor. [PDF]

Indian J Ophthalmol
Verma L, Singh S, Ramachandran O.
europepmc   +1 more source

From anti-drug antibody incidence to clinical relevance: interpreting highly sensitive immunogenicity assays in biosimilars. [PDF]

Bioanalysis
Krishnan A, Bp S, Mehta G, Ramaswamy S, Chakraborty S, Mandal S.   +5 more
europepmc   +1 more source

A retrospective study of the efficacy and safety of rituximab biosimilar for the treatment of membranous nephropathy. [PDF]

BMC Pharmacol Toxicol
Zou YZ, Du XL, Wang SH, Dai R, Xiao R, Wang B.   +5 more
europepmc   +1 more source

Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis. [PDF]

United European Gastroenterol J
Hart A, Navabi S, D'Haens G, Matsuoka K, Martín-Arranz MD, Atreya R, Samaan KH, Dhesi E, Redondo I, Zhu B, Paulissen J, Zaremba-Pechmann L, Baygani S, Limdi J, Laharie D, Danese S.   +15 more
europepmc   +1 more source

Horizon scan of the clinical development landscape of biosimilar products in the UK and EU. [PDF]

Int J Technol Assess Health Care
Hussain A, Fairbairn R, Khan SK.
europepmc   +1 more source

Aflibercept biosimilar use and real-world outcomes in various retinal diseases: the AURA Korea study. [PDF]

Sci Rep
Song JR, Jeon J, Baek SC, Sharma A, Sagong M, Lee CS, Woo SJ, International Retina Biosimilar Study Group (Inter BIOS Group).   +7 more
europepmc   +1 more source

Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis. [PDF]

Adv Ther
Yamauchi PS, Chow V, Mytych DT, Zhou M, Radziszewski W.   +4 more
europepmc   +1 more source

Advancing PEGylated Drug Evaluation: A Novel Approach to Pegfilgrastim Pharmacokinetic Assessment. [PDF]

Clin Transl Sci
Svyatova E, Shi D, Shah A, Howard KE.
europepmc   +1 more source